IBDQ-32 Accurately Detects Treatment Response in Ulcerative Colitis

The IBDQ-32 should be used in clinical trials for patients with ulcerative colitis, given its accuracy for detecting changes and response to treatment.

The 32-item Inflammatory Bowel Disease Questionnaire (IBDQ-32) is effective for detecting changes and treatment response in patients with ulcerative colitis (UC), according to study results presented at the Advances in Inflammatory Bowel Diseases (AIBD) 2022 conference, held from December 5 to 7, 2022, in Orlando, Florida.

Researchers conducted a systematic review and meta-analysis regarding the ability of the IBDQ-32 to detect changes in UC health indicators. A search for relevant published articles was performed in the PubMed, Embase, and CENTRAL databases through 2021.

Eligible studies reported on the association of change in IBDQ-32 scores with change in UC health indicators in adults or IBDQ-32 responder analyses in randomized controlled trials (RCTs) of adults with UC. The RCTs were included in a random effects meta-analysis that compared patients with a response on the IBDQ-32 (≥16 points) between the active treatment and placebo groups.

Future research should examine IBDQ-32 responsiveness in the context of real-world evidence studies.

A moderator analysis was used to compare IBDQ-32 responders who received efficacious treatments and nonefficacious treatments. Linear meta-regression analysis assessed the association between a continuous predictor of the primary endpoint of treatment efficacy and proportion of IBDQ-32 responders in active treatment vs placebo.

A total of 15 articles correlating changes in IBDQ-32 with changes in UC health were included. Consistent moderate-to-strong associations were observed in the expected direction between changes in IBDQ-32 total scores and changes in other UC health measures.

The change in IBDQ-32 total scores was associated with the change in patient-reported symptoms (correlations: r=0.57; P =-.64), clinical response and remission on disease activity indices (partial Mayo score; correlations: P =-.53,-.59), and remission and mucosal healing on endoscopic activity indices (correlations: P =-.37, -.50). Changes in patient-reported symptoms or disease activity indices were associated with clinically meaningful mean changes in IBDQ-32 total scores (22.3-50.1 points).

Participants who achieved clinical remission according to disease activity indices or mucosal healing based on Mayo endoscopic subscores had significantly increased mean changes in IBDQ-32 total scores vs patients who did not achieve remission or mucosal healing.

“Evidence supports the ability of the IBDQ-32 to detect change and response to treatment among patients with UC, supporting the use of the IBDQ-32 in clinical trials,” the study authors noted. “Future research should examine IBDQ-32 responsiveness in the context of real-world evidence studies.”


Dubinsky M, Rice A, Yarlas A, et al. Systematic literature review of the ability of the IBDQ-32 to detect meaningful change in ulcerative colitis health indicators. Abstract presented at: AIBD 2022; December 5-7, 2022; Orlando, FL. Abstract 84.